{
    "nctId": "NCT02394496",
    "briefTitle": "Overcoming Endocrine Resistance in Metastatic Breast Cancer",
    "officialTitle": "A Randomized Trial With Factorial Design Comparing Fulvestrant \u00b1 Lapatinib \u00b1 Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 396,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of written informed consent\n2. Histological/cytological confirmation of breast cancer\n3. Documented positive hormone receptor status (ER+ve and/or PgR+ve) of primary or metastaic tumor issue, according to the local laboratory parameters\n4. Postmenopausal women\n5. Confirmed progression of disease after an adjuvant therapy or a therapy for metastatic disease with an aromatase inhibitors\n6. Patients demonstrating prior response to AI therapy\n7. Patients with measurable disease as per RECIST criteria /Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of measurable disease as defined by RECIST criteria.\n8. May have received prior radiotherapy as treatment for primary or metastatic tumour; however, is not required for study entry;\n9. Life expectancy of at least 8 months\n10. WHO performance status 0, 1 or 2\n11. Patients with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence.\n12. Are able to swallow and retain oral medication;\n13. Are able to complete all screening assessments as outlined in the protocol;\n14. Patients must have normal organ and marrow function\n15. Left ventricular ejection fraction (LVEF) within the institutional normal range\n\nExclusion Criteria:\n\n1. Previous therapy with Fulvestrant and/or Lapatinib;\n2. Patients with HER 2 overexpressing, either IHC 3+ or FISH +;\n3. Concurrent non study anti-cancer therapy (\n4. Have unresolved or unstable, serious toxicity from prior administration\n5. Have malabsorption syndrome,\n6. Have a concurrent disease or condition that would make the patient inappropriate for study participation,\n7. Have an active or uncontrolled infection;\n8. Have dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;\n9. Have a known history of uncontrolled or symptomatic angina, arrhythmias, or CHF;\n10. Receive concurrent treatment with an investigational agent or participate in another clinical trial;\n11. Receive concurrent treatment with prohibited medications\n12. Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication;\n13. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to fulvestrant, aromatase inhibitors or lapatinib or excipients.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}